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Abstract The aim of this study was to evaluate the risk of
recurrent ischaemic cerebrovascular events (stroke or tran-
sient ischaemic attack (TIA)) in patients with patent fora-
men ovale (PFO) or atrial septal aneurysm (ASA) treated
with different therapeutic regimens. We enrolled 86
patients aged 18–60 years with an unexplained ischaemic
stroke or TIA referred to our inpatient department in the
period May 1994–December 1999. Follow-up lasted until
April 2003. Patients were excluded if the stroke or TIA
was related to large-artery atherosclerosis, small artery
occlusion, major cardiac sources of embolism or other
uncommon causes. During a follow-up (mean±SD) of
64.1±28.8 months (range 8.1–105.6) a recurrent ischaemic
cerebrovascular event occurred in 11/86 patients (12.8%)
(5 TIA and 6 strokes). Eight events (4 TIA, 4 strokes)
occurred in the 59 patients with PFO alone, three (1 TIA,
2 strokes) in the 21 with PFO plus ASA and none in the 6
patients with ASA alone. In the overall population the
cumulative risk of recurrent stroke/TIA was 1.2% at 2
years, 5.5% at 4 years, 7.6% at 6 years and 23.6% at 8
years, and was similar in patients with PFO alone vs.
patients with PFO plus ASA (9.0% vs. 6.1% at 6 years,
26.0% vs. 23.1% at 8 years; p>0.05). Nine cerebral
ischaemic events (4 TIA, 5 strokes) occurred in the 48
patients treated with antiplatelet drugs (7 in patients with
PFO, 2 in patients with PFO plus ASA), and two (1 TIA, 1
stroke) in the 17 patients treated with oral anticoagulants
(1 with PFO, 1 with PFO plus ASA). No events occurred
in patients submitted to transcatheteral closure.
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Introduction
In the last decade the role of patent foramen ovale (PFO)
and atrial septal aneurysm (ASA) in the aetiopathogenesis
of ischaemic stroke has been largely investigated [1].
Several studies have estimated the recurrence risk of stroke
or transient ischaemic attack (TIA) in patients with PFO.
Comess et al. found a high rate of recurrent ischaemic
cerebrovascular events (ICVE) in patients with ASA or
interatrial shunt [2]. A recurrence rate of 3.4% per year
was reported by Mas and Zuber [3], similar to the 3.8% per
year of the casistic from Bogousslavsky et al. [4]. A recent
large prospective study has reported that the frequency of
recurrent stroke is low in patients with isolated PFO treat-
ed with aspirin [5]. Moreover, the coexistence of ASA
identified a subgroup in which preventive strategies other
than antiplatelet drugs such as oral anticoagulants, surgical
or transcatheteral closure of PFO have to be considered
[5]. However there are no clear-cut data on what solution
is better in the management of patients with PFO plus ASA
[6–9]. In the present work we have estimated the risk of
recurrent ICVE (stroke or TIA) in patients with PFO or
ASA treated with different therapies.
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Patients and methods
Case study
We enrolled 86 patients aged 18–60 years with unexplained
ischaemic stroke (defined as a neurologic deficit that lasted more
than 24 h) or TIA with the presence of PFO or ASA. These
patients were referred to our inpatient department (First Division
of Neurology, San Giovanni Battista Hospital, Turin, Italy) in the
period May 1994–December 1999. Follow-up lasted until 30
April 2003.
Data collection
Stroke risk factors, previous vascular history, clinical and instru-
mental findings, and stroke severity [10] were systematically
recorded. Cranial CT scan was performed at admission. If nega-
tive, a second CT scan was performed 48 h after onset. Brain
MRI was performed in 50% of the cases, in patients with TIA
and if the second cranial CT scan failed in revealing an
ischaemic lesion related to the clinical picture.
All patients underwent a standardised diagnostic workup to
highlight definite causes of stroke. Diagnostic protocol consisted of
routine blood examinations, complete coagulation screening
(including tests for protein S, protein C and antithrombin III defi-
ciency and antiphospholipid antibodies), 12-lead electrocardio-
gram, transthoracic and transoesophageal echocardiogram. Also, an
extracranial duplex ultrasonography (100%), a conventional (20%)
or a MR angiography (40%) were performed within one month of
the onset. Additional investigations, namely to detect asymptomatic
deep vein thrombosis, were left to the discretion of the physicians
as failure to document venous thrombi does not exclude paradoxi-
cal embolism in PFO patients [11]. Patient were excluded if the
diagnostic workup revealed the following causes of stroke defined
according to TOAST criteria [12]: (1) large-artery atherosclerosis
(defined as >50% stenosis or occlusion of the corresponding ves-
sel); (2) small artery occlusion stroke (defined as a small deep
infarct less than 15 mm in diameter in a patient with hypertension
or diabetes); (3) major cardiac sources of embolism, such as atrial
fibrillation, recent (within four months before the stroke) myocar-
dial infarction, dilated cardiomyopathy, mitral stenosis, mitral or
aortic vegetations or prosthesis, left atrial or left ventricular throm-
bus or tumour, spontaneous echo contrast in the left atrium, akinet-
ic left ventricular segment and complex atheroma of the aortic arch;
(4) other definite causes of stroke, such as nonatherosclerotic arte-
riopathies (e.g., dissection), coagulopathies (e.g., the antiphospho-
lipid–antibody syndrome) or systemic disorders(e.g., migrainous
infarction). Clinical and imaging data were reviewed by two neu-
rologists unaware of the echocardiographic findings.
Echocardiography
All patients underwent transthoracic and transoesophageal echocar-
diography, performed by experienced cardiologists according to the
protocol reported in our previous study [13]. Examinations were
recorded on videotape and reviewed by two independent examiners
unaware of the patients’ clinical data and outcome.
According to our previous work [13] and to other Authors
[15–17], the entity of the right-left shunt was defined “small” if
less than 20 microbubbles appeared in the left atrium upon
release of a Valsalva manoeuvre and “large” if at least 20
microbubbles appeared after Valsalva or if a right to left shunt
was evident at rest. An ASA was diagnosed when the atrial sep-
tum extended at least for 11 mm either into the left or the right
atrium or both.
Treatment and follow-up
Each physician autonomously decided which therapy
(antiplatelet drugs or anticoagulant) to employ. In general,
according to current recommendations [14], patients with small
or isolated PFO were preferentially treated with antiplatelet
drugs while patients with large PFO or PFO associated with
ASA were preferentially treated with oral anticoagulants.
Transcatheteral closure of the anomaly was considered in the
presence of: (a) recurrent events during drug treatment; (b) mul-
tiple non-lacunar ischaemic areas on neuroimaging; (c) right-left
shunts classified as “large entity shunt” or associated with ASA.
Patients were annually evaluated by an expert neurologist (70%
of the cases) or, if not possible, by phone interview (30% of the
cases). The following endpoints were systematically recorded:
recurrent stroke or TIA, peripheral embolism, myocardial infarc-
tion and death.
Antiplatelet drugs were started during the acute phase
whereas anticoagulants were initiated (mean±SD) 21±10.7 days
after the first event with no significant differences among the
three groups.
Statistical analysis
Chi-square test, Fisher’s exact test, t-test for unpaired data and
variance analysis were employed where appropriate. Kaplan-
Meier survival curves were applied to assess the risk of recurrent
stroke/TIA according to different subgroups. Differences among
groups were explored by the logrank test. The predictive value
of each atrial septal defect (PFO alone, ASA alone, PFO plus
ASA) and of the shunt entity with respect to recurrent
stroke/TIA was assessed using the Cox proportional-hazard
model. All tests were two-tailed and the significance level was
defined as p<0.05.
Results
Study population
The 86 patients [age (mean±SD): 45±13.5 years; 43
males, 43 females) were divided into three groups accord-
ing to the atrial septal abnormality: 59 patients had PFO
alone, 6 had ASA alone, and 21 had PFO and ASA.
Baseline features and vascular risk factors of the patients
are detailed in Table 1. There were no significant differ-
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ences among the three groups. About 24% of the PFO
patients also had an ASA whereas most of the ASA
patients (77.7%) also had a shunt. About three-quarters of
the patients were aged less than 55 years. A large shunt
was evidenced in 52.4% of patients with PFO plus ASA
vs. 45.8% of patients with PFO alone (p>0.05). Starting
from the employed treatment, the study population was
divided into three groups. Group A included patients treat-
ed with antiplatelet drugs (48 cases: 38 with PFO alone, 6
with PFO plus ASA, 4 with ASA alone). Group B includ-
ed patients treated with oral anticoagulants (warfarin with
target INR of 2–3) (17 cases: 7 with PFO alone, 8 with
PFO plus ASA, 2 with ASA alone). Group C included
patients who underwent transcatheteral closure (21 cases:
14 with PFO alone, 7 with PFO plus ASA).
Recurrent events
The Kaplan-Meier estimation of the risk of a second cere-
bral ischaemic event (stroke/TIA) according to atrial sep-
tal defects is shown in Table 2 and Fig. 1. During a fol-
low-up (mean±SD) of 64.1±28.8 months (range
8.1–115.6), a second event occurred in 11/86 patients
(12.8%) (5 TIA and 6 strokes).
Eight events (4 TIA, 4 strokes) recurred in the 59
patients with PFO alone, three (1 TIA, 2 strokes) in the 21
with PFO plus ASA and none in the 6 patients with ASA
alone.
In the overall population the cumulative risk of recur-
rent stroke/TIA was 1.2% at 2 years, 5.5% at 4 years,
7.6% at 6 years and 23.6% at 8 years, and was similar in
Table 1 Baseline characteristics, and vascular risk factors and treatment in patients with atrial septal abnormalities
PFO PFO+ASA ASA Total (%)
n (%) n (%) n (%) n (%) p value
59 (68.6) 21 (24.4) 6 (7) 86 (100)
Males 30 (51) 9 (43) 4 (66.6) 43 (50) NS
Age ≤55 years 48 (81.4) 14 (66.7) 3 (50) 65 (75.6) NS
Age >55 years 11 (18.6) 7 (33.3) 3 (50) 21 (24.4) NS
Age mean (years) 42.7±12.5 49.1±15.4 52.8±9.8 45.0±13.5
Hypertension 13 (24.5) 3 (14.3) 2 (3.3) 18 (22.5) NS
Diabetes 2 (4) 2 (9.5) 1 (16.6) 5 (6.25) NS
Dyslipidaemia 11 (21) 1 (5) 1 (16.6) 13 (16.25) NS
Smoke 19 (36) 8 (38) 1 (16.6) 28 (35) NS
Stroke 41 (69.5) 14 (66.7) 5 (83.4) 60 (69.8) NS
TIA 14 (23.8) 7 (33.3) 1 (16.6) 22 (25.6) NS
Shunt <20 bubbles 32 (54.2) 10 (47.6) – 42 (52.5) NS
Shunt >20 bubbles or at rest 27 (45.8) 11 (52.4) – 38 (40) NS
Antiplatelets 38 (64.5) 6 (28.7) 4 (66,7) 48 (55.8)
Oral anticoagulants 7 (11.8) 8 (38.0) 2 (33.3) 17 (19.8)
TCC 14 (23.7) 7 (33.3) 0 21 (24.4)
Mean follow-up (months±SD) 62.7±29.9 63.5±28.0 79.6±15.5 64.1±28.8
TCC, transcatheteral closure
Table 2 Kaplan-Meier estimation of the risk of a second ICVE, according to atrial septal abnormalities
N ICVE Mean follow-up Cumulative risk (%)
(years)
At 2 years At 4 years At 6 years At 8 years
PFO 59 8  (13.5%) 4.7 1.8  (0–4.1) 6.0  (2.6–9.4) 9.0  (4.6–13.4) 26.0  (16.4–35.6)
PFO+ASA 21 3  (14.2%) 4.3  0 6.1  (0.2–12) 6.1  (0.2–12) 23.1  (6.9–39.3)
ASA 6 0 5.2 0 0 0 0
TOTAL 86 11  (12.7%) 4.7 1.2  (0–2.8) 5.5  (2.8–8.2) 7.6  (4.3–10.9) 23.6  (15.8–31.4)
ICVE, ischaemic cerebrovascular events (stroke or TIA)
patients with PFO alone versus patients with PFO plus
ASA (9.0% vs. 6.1% at 6 years, 26.0% vs. 23.1% at 8
years; p>0.05). As no stroke/TIA event occurred in
patients with isolated ASA, the cumulative risk of recur-
rence was zero (no event occurred in this group).
Cox analysis (Table 3) revealed that the presence of
ASA or PFO – both isolated and associated – was not
associated with an increased risk of recurrent stroke/TIA.
Nevertheless, there was a clear trend for large shunts (as
defined in the Methods section) to predict an increased risk
of recurrent stroke/TIA (hazard ratio: 1.87; p=0.05).
Neither gender nor age were predictors of recurrent cere-
bral ischaemic events.
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Effect of treatment
Kaplan-Meier estimation of the risk of a second stroke/TIA
according to the different treatments is detailed in Table 4
and Fig. 2. Nine cerebral ischaemic events (4 TIA, 5
strokes) occurred in the 48 patients treated with antiplatelet
drugs (7 in patients with PFO, 2 in patients with PFO plus
ASA), and two (1 TIA, 1 stroke) in the 17 patients treated
with oral anticoagulants (1 with PFO, 1 with PFO plus
ASA). No events occurred in patients submitted to tran-
scatheteral closure. With respect to the whole population,
18.7% of the antiaggregant-treated patients and 11.7% of
the anticoagulant-treated reported a recurrent stroke/TIA.
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Fig. 1 Kaplan-Meier curve
(probability to remain free
from a second ICVE) accord-
ing to atrial septal abnormal-
ities
Table 3 Cox proportional-Hazard models of the predictors of a second ICVE in patients with atrial septal abnormalities
Hazard ratio (95% CI) p value
Age 1.07 0.97–1.06 NS
Male sex 1.67 0.40–6.82 NS
PFO alone 1.33 0.15–11.5 NS
ASA alone 1.19 0.16–8.7 NS
PFO and ASA 1.39 0.15–12.8 NS
Shunt >20 bubbles or at rest 1.87 0.96–3.66 0.05
Table 4 Kaplan-Meier estimation of the risk of a second ICVE, according to different therapies
n ICVE Mean Cumulative 
follow-up risk (%)
(years)
At 2 years At 4 years At 6 years At 8 years
Group A: AP 48 9 (18.7%) 4.8 2.1 (0–4.6) 8.7 (4.5–13.2) 8.7 (4.5–13.2) 29.6 (19.9–49.5)
Group B: OAC 17 2 (11.7%) 4.6 0 0 0 23.2 (5.9–40.5)
Group C: TCC 21 0 2.6 0 0 0 –
AP, antiplatelet drugs; OAC, oral anticoagulants; TCC, transcatheteral closure
0        2          4           6           8        10       12
1
0,8
0,6
0,4
0,2
0
The cumulative risk of recurrence was not significantly dif-
ferent in group A versus group B (29.6% and 23.2 %
respectively). Kaplan-Meier estimation of the risk of a sec-
ond stroke/TIA with respect to the type of atrial anomaly
and the treatment is detailed in Table 5. The highest likeli-
hood of recurrence was found in patients with PFO plus
ASA treated with antiplatelet drugs (cumulative risk of 20%
at 4 years, 73% at 8 years). In anticoagulant-treated patients
with PFO plus ASA, antiaggregant-treated patients with
PFO alone and anticoagulant-treated patients with PFO
alone the cumulative risk of recurrence was similar (21.6%,
27.1% and 24.8% at 8 years, respectively; p>0.05). No
event was reported in patients submitted to transcatheteral
closure [follow-up (mean±SD) 33.2.±17.3 months].
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Fig. 2 Kaplan-Meier curve (proba-
bility to remain free from a second
ICVE) according to the different
therapies
Table 5 Kaplan-Meier estimation of the risk of a second ICVE, according to atrial septal abnormalities and the different therapies
N ICVE Mean Cumulative
follow-up risk (%)
(years)
At 2 years At 4 years At 6 years At 8 years
PFO (AP) 38 7 4.8 2.6 (0-5.7) 8.1 (3.6-12.6) 8.1 (3.6-12.6) 27.1 (16.7-37.5)
PFO (OAC) 7 1 4.6 0 0 0 24.8 (6.1-43.5)
PFO (TCC) 14 0 2.5 0 0 0 -
PFO total 59 8 4.7 1.8  (0-4.1) 6.0 (2.6-9.4) 9.0 (4.6-13.4) 26.0 (16.4-35.6)
PFO+ASA (AP) 6 2 4.8 0 20.0 (2.1-37.9) 20.0 (2.1-37.9) 73.3 (48.7-97.9)
PFO+ASA (OAC) 8 1 4.6 0 0 0 21.6 (12.5-30.7)
PFO+ASA (TCC) 7 0 2.6 0 0 0 -
PFO + ASA total 21 3 4.3 0 6.1 (0.2-12) 6.1 (0.2-12) 23.1 (6.9-39.3)
ASA (AP) 4 0 5.3 0 0 0 0
ASA (OAC) 2 0 5.0 0 0 0 -
ASA (TCC) 0 0 0 - - - -
ASA total 6 0 5.2 0 0 0 -
TOTAL 86 11 4.7 1.2 (0-2.8) 5.5 (2.8-8.2) 7.6 (4.3-10.9) 23.6 (15.8-31.4)
ICVE, ischaemic cerebrovascular events (stroke or TIA); PFO, patent foramen ovale; ASA, atrial septal aneurysm
(AP)
(OAC)
(TCC)
AP, antiplatelet drugs; OAC, oral anticoagulants; TCC, transcatheteral closure
Discussion
In our study the cumulative risk of stroke/TIA was 1.2% at
2 years, 5.5% at 4 years, 7.6% at 6 years and 23.6% at 8
years with a mean annual rate of 2.9%, with no significant
differences between patients with PFO alone and those
with PFO plus ASA. However, the presence of a large
shunt may represent a predictor of increased risk of recur-
rent stroke/TIA. The significance of the high risk of recur-
rence at 8 years (23.6%) is limited by the small number of
patients.
In patients with stroke or TIA without arterial and
major cardiac sources of embolism in a previous work we
found a frequency of PFO of 31.4% that rose to 40.6% in
patients with non-lacunar (presumably embolic)
stroke/TIA [13]. Reported rates of PFO occurrence in
patients with cryptogenic stroke range from 31 to 77% [1].
In this study, we selected patients aged less than 60
years because the higher prevalence of large-vessel ather-
osclerosis or small-artery disease in the elderly population
makes the diagnosis of cryptogenic stroke less probable.
Notably, most of our patients were aged less than 55 years
and the association of PFO with cryptogenic stroke has
been consistently reported in this age group [1]. Little data
are available on the recurrence of cerebral ischaemic
events (stroke/TIA) in patients with PFO and ASA.
Comess et al. observed a high rate of recurrent ICVE
in patients with either ASA (16.9/100 person-years) or
right-left atrial shunt (14.4/100 person-years) [2]. No dif-
ference in frequency of patients taking aspirin or warfarin
was reported but the actual therapy was not reported in
detail.
In the Lausanne study, during a mean follow-up of 3
years, the rate of recurrent events was 3.8% per year in 135
patients with PFO and/or ASA independent from the
employed strategies (antiplatelet drugs, anticoagulants or
surgical closure) [4]. A French study prospectively evalu-
ated 132 patients with PFO, ASA or both (126 of whom
received antiplatelet drugs or anticoagulants) for 22.6
months [3]. Their average annual rate of stroke/TIA was
3.4% and the association of PFO plus ASA was particular-
ly ominous.
A number of reports have recently emphasised the size
of the right to left shunt as the crucial factor for paradoxi-
cal embolism in stroke patients [15–18].
More recently, De Castro et al. reported a higher recur-
rence risk (12.5%) at 3 years in the subgroup of patients
with right-left shunt at rest or with “high interatrial mem-
brane motility” [19].
Despite these results, the better preventive strategy for
stroke patients with PFO or ASA is yet to be established
[20]. The absolute risk of recurrent stroke/TIA in patients
with PFO is low according to different retrospective stud-
ies [20]. Usually, these patients are empirically treated
with antiplatelet drugs, anticoagulants, transcatheteral or
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surgical closure of the septal defect. Current available
guidelines suggest anticoagulants or transcatheteral clo-
sure in patients at higher risk (PFO plus ASA, large PFO,
multiple infarction) [14]. In the present study patients
with PFO alone were at low risk of recurrent stroke/TIA
independently from the employed therapy (antiplatelet
drugs or anticoagulants). Anyway, the value was not neg-
ligible because about 3% of patients experienced a new
cerebrovascular event. No event recurred in patients with
ASA alone. There was no difference in the risk of recur-
rence between patients treated with antiplatelet drugs vs.
oral anticoagulant but patients with PFO plus ASA treat-
ed with antiplatelet drugs showed a high likelihood of
recurrence with a cumulative risk of 20% at 4 years and of
73% at 8 years.
In the prospective study by Mas et al. [5] secondary
prevention with aspirin was found to be insufficient in
young patients with isolated PFO and a single unexplained
stroke. They also reported that patients with PFO plus
ASA represented a subgroup with a higher risk of recur-
rent stroke that could benefit from more aggressive thera-
peutic strategies (long-term anticoagulation, surgical or
transcatheteral closure of the PFO).
In the recent PICCS study the high prevalence of PFO
with cryptogenic stroke was confirmed: neither the PFO
size nor the association with ASA conferred an additional
risk of recurrent events and the recurrence rate was similar
in patients randomised to anticoagulant and to antiaggre-
gant therapy [21].
In our study no recurrent stroke/TIA occurred in the 14
patients submitted to transcatheter closure during a mean
follow-up period of 33 months. It is noteworthy that these
patients were considered at high risk because of a “large”
shunt or multiple ischaemic lesions. In the initial experi-
ence with surgical closure, Devuyst et al. reported no
recurrent event in 32 patients [22], but papers by Homma
et al. (19.5% recurrence rate at 13 months) and the Mayo
Clinic (7.5% at 1 year and 16.6% at 4 years) were disap-
pointing [23, 24].
Surgery has been superseded by the percutaneous tran-
scatheteral approach due to the absence of open-heart
surgery [25]. After early experiences in which the success
in the reduction of ischaemic events was balanced by a
high rate of periprocedural complications, subsequent
studies using multiple device systems have demonstrated
similar rates of recurrent thromboembolic events [26–33].
The rate of recurrent cerebral ischaemic events was
3.2% per year in the 63 patients treated by Hung et al. [32].
In the case report of Meier et al. [33], the actuarial free-
dom from recurrent embolic events was 95.1% at 1 year,
decreased to 90.6% at 2 years and remained stable there-
after (90.6% at 6 years). The present study has some limi-
tations. Although its follow-up period was longer with
respect to most literature reports, it was not a randomised
study. Besides, the follow-up was shorter for patients sub-
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mitted to transcatheteral closure and the number of cases
in each treatment group was low to gain definite indica-
tions on the best treatment to reduce recurrent stroke/TIA.
Anyway, our results seem to confirm the high risk of recur-
rence in patients with PFO plus ASA if treated with anti-
aggregants and the importance of an accurate diagnostic
work-up to exclude any determined cause of ischaemic
stroke. Moreover our data confirm the safety of tran-
scatheteral closure, which is a reasonable alternative ther-
apy in the prevention of presumed paradoxical embolism
in the presence of an atrial septal abnormalities [34, 35].
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